These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2252956)
21. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Schwarz RE; Vujanovic NL; Hiserodt JC Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350 [TBL] [Abstract][Full Text] [Related]
22. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related]
23. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells. Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622 [TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604 [TBL] [Abstract][Full Text] [Related]
27. Effects of bone marrow transplantation and polyinosinic-polycytidylic acid (poly I:C) on the rescue of animals from busulfan-induced NK suppression. Bhoopalam N; Fried W; Benson D; Barone-Verales J; Price K Exp Hematol; 1989 May; 17(4):357-63. PubMed ID: 2651135 [TBL] [Abstract][Full Text] [Related]
28. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. Agah R; Malloy B; Kerner M; Mazumder A J Immunol; 1989 Nov; 143(9):3093-9. PubMed ID: 2809219 [TBL] [Abstract][Full Text] [Related]
29. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. Kasid A; Bell GI; Director EP J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414 [TBL] [Abstract][Full Text] [Related]
30. Interleukin-2 in bone marrow transplantation: preclinical studies. Charak BS; Choudhary GD; Tefft M; Mazumder A Bone Marrow Transplant; 1992 Aug; 10(2):103-11. PubMed ID: 1326364 [TBL] [Abstract][Full Text] [Related]
31. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model. Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260 [TBL] [Abstract][Full Text] [Related]
32. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. Mulé JJ; Krosnick JA; Rosenberg SA J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444 [TBL] [Abstract][Full Text] [Related]
33. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation. Tam YK; Klingemann HG Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103 [TBL] [Abstract][Full Text] [Related]
34. Effects of ultraviolet-B irradiation on human LAK and NK cytotoxic activity. Yaron I; Zakheim AR; Oluwole SF; Hardy MA Cell Immunol; 1995 Oct; 165(2):168-76. PubMed ID: 7553880 [TBL] [Abstract][Full Text] [Related]
35. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12. Wong EK; Eaves C; Klingemann HG Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997 [TBL] [Abstract][Full Text] [Related]
36. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798 [TBL] [Abstract][Full Text] [Related]
37. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213 [TBL] [Abstract][Full Text] [Related]
38. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004 [TBL] [Abstract][Full Text] [Related]
39. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145 [TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]